PL3475272T3 - Pochodne ftalazyny jako inhibitory parp1, parp2 i/lub tubuliny przydatne w leczeniu nowotworu - Google Patents
Pochodne ftalazyny jako inhibitory parp1, parp2 i/lub tubuliny przydatne w leczeniu nowotworuInfo
- Publication number
- PL3475272T3 PL3475272T3 PL17737132.5T PL17737132T PL3475272T3 PL 3475272 T3 PL3475272 T3 PL 3475272T3 PL 17737132 T PL17737132 T PL 17737132T PL 3475272 T3 PL3475272 T3 PL 3475272T3
- Authority
- PL
- Poland
- Prior art keywords
- parp2
- parp1
- tubulin
- inhibitors
- cancer
- Prior art date
Links
- 101100407084 Caenorhabditis elegans parp-2 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102000004243 Tubulin Human genes 0.000 title 1
- 108090000704 Tubulin Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 101150063226 parp-1 gene Proteins 0.000 title 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662354449P | 2016-06-24 | 2016-06-24 | |
| US201662426095P | 2016-11-23 | 2016-11-23 | |
| PCT/US2017/039119 WO2017223516A1 (en) | 2016-06-24 | 2017-06-23 | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3475272T3 true PL3475272T3 (pl) | 2024-04-29 |
Family
ID=59297390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17737132.5T PL3475272T3 (pl) | 2016-06-24 | 2017-06-23 | Pochodne ftalazyny jako inhibitory parp1, parp2 i/lub tubuliny przydatne w leczeniu nowotworu |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11072600B2 (enExample) |
| EP (1) | EP3475272B1 (enExample) |
| JP (2) | JP7033588B2 (enExample) |
| KR (1) | KR102494294B1 (enExample) |
| CN (1) | CN109843874B (enExample) |
| AU (1) | AU2017280334C1 (enExample) |
| ES (1) | ES2964531T3 (enExample) |
| HU (1) | HUE066216T2 (enExample) |
| IL (1) | IL263917B (enExample) |
| MX (2) | MX387726B (enExample) |
| PL (1) | PL3475272T3 (enExample) |
| PT (1) | PT3475272T (enExample) |
| SG (1) | SG11201811393WA (enExample) |
| WO (1) | WO2017223516A1 (enExample) |
| ZA (2) | ZA201808562B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3298005B1 (en) | 2015-05-21 | 2024-01-24 | The Regents of The University of California | Anti-cancer compounds |
| EP3383852A4 (en) * | 2015-11-30 | 2019-08-28 | Children's Medical Center Corporation | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
| EP3475272B1 (en) | 2016-06-24 | 2023-09-13 | The Regents of The University of California | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
| JP7372253B2 (ja) * | 2018-04-05 | 2023-10-31 | ノビガ・リサーチ・エービー | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ |
| CN112574122B (zh) * | 2019-09-27 | 2024-05-31 | 上海天慈国际药业有限公司 | 一种奥拉帕尼关键中间体的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3401171A (en) | 1966-03-11 | 1968-09-10 | Smithkline Corp | 2-amidobenzimidazoles |
| SU1019810A1 (ru) | 1981-07-28 | 1991-04-07 | Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского | Метиловый эфир 5(6)-[1-(2Н)-фталазинонил-4]-1Н-бензимидазолил-2-карбаминовой кислоты, обладающий антигельминтной активностью |
| SU1218649A1 (ru) | 1984-09-19 | 1991-04-30 | Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского | Способ получени метилового эфира 5(6)-[1(2Н)-фталазинонил-4-]-1Н-бензимидазолил-2-карбаминовой кислоты формулы |
| JP2002502844A (ja) | 1998-02-03 | 2002-01-29 | ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト | ５員複素環縮合ベンゾ誘導体、その調製及び医薬品としてのそれらの使用 |
| KR20010101675A (ko) | 1999-01-26 | 2001-11-14 | 우에노 도시오 | 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제 |
| DE19907813A1 (de) | 1999-02-24 | 2000-08-31 | Boehringer Ingelheim Pharma | Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel |
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| EP1633724B1 (en) | 2003-03-12 | 2011-05-04 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2005112932A2 (en) | 2004-05-07 | 2005-12-01 | Exelixis, Inc. | Raf modulators and methods of use |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| CN101291928A (zh) * | 2005-10-19 | 2008-10-22 | 库多斯药物有限公司 | 4-杂芳甲基取代的酞嗪酮衍生物 |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| JP5492183B2 (ja) * | 2008-03-27 | 2014-05-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン |
| CA3012137A1 (en) | 2010-01-29 | 2011-08-04 | Metanomics Gmbh | Means and methods for diagnosing heart failure in a subject |
| CN102372706A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CA2875025C (en) | 2011-05-31 | 2021-08-03 | Newgen Therapeutics, Inc. | Tricyclic inhibitors of poly(adp-ribose)polymerase |
| KR101546743B1 (ko) * | 2012-01-16 | 2015-08-24 | 한국과학기술원 | 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물 |
| AU2013368842B2 (en) * | 2012-12-31 | 2015-11-12 | Cadila Healthcare Limited | Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| EP3475272B1 (en) * | 2016-06-24 | 2023-09-13 | The Regents of The University of California | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
-
2017
- 2017-06-23 EP EP17737132.5A patent/EP3475272B1/en active Active
- 2017-06-23 IL IL263917A patent/IL263917B/en unknown
- 2017-06-23 JP JP2019519615A patent/JP7033588B2/ja active Active
- 2017-06-23 KR KR1020197002267A patent/KR102494294B1/ko active Active
- 2017-06-23 PT PT177371325T patent/PT3475272T/pt unknown
- 2017-06-23 US US16/310,606 patent/US11072600B2/en active Active
- 2017-06-23 AU AU2017280334A patent/AU2017280334C1/en active Active
- 2017-06-23 PL PL17737132.5T patent/PL3475272T3/pl unknown
- 2017-06-23 HU HUE17737132A patent/HUE066216T2/hu unknown
- 2017-06-23 CN CN201780051422.3A patent/CN109843874B/zh active Active
- 2017-06-23 ES ES17737132T patent/ES2964531T3/es active Active
- 2017-06-23 SG SG11201811393WA patent/SG11201811393WA/en unknown
- 2017-06-23 MX MX2018015893A patent/MX387726B/es unknown
- 2017-06-23 WO PCT/US2017/039119 patent/WO2017223516A1/en not_active Ceased
-
2018
- 2018-12-17 MX MX2021013641A patent/MX2021013641A/es unknown
- 2018-12-19 ZA ZA2018/08562A patent/ZA201808562B/en unknown
-
2019
- 2019-07-30 US US16/526,620 patent/US10640493B2/en active Active
-
2021
- 2021-07-15 US US17/376,577 patent/US12145925B2/en active Active
- 2021-11-26 JP JP2021192564A patent/JP2022037004A/ja active Pending
-
2023
- 2023-01-25 ZA ZA2023/01066A patent/ZA202301066B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201808562B (en) | 2023-12-20 |
| JP7033588B2 (ja) | 2022-03-10 |
| US11072600B2 (en) | 2021-07-27 |
| EP3475272B1 (en) | 2023-09-13 |
| SG11201811393WA (en) | 2019-01-30 |
| WO2017223516A1 (en) | 2017-12-28 |
| IL263917B (en) | 2022-07-01 |
| BR112018076821A2 (pt) | 2019-04-02 |
| KR102494294B1 (ko) | 2023-01-31 |
| US10640493B2 (en) | 2020-05-05 |
| MX2018015893A (es) | 2019-08-01 |
| AU2017280334A1 (en) | 2019-01-17 |
| IL263917A (en) | 2019-02-28 |
| HUE066216T2 (hu) | 2024-07-28 |
| JP2022037004A (ja) | 2022-03-08 |
| US20190352283A1 (en) | 2019-11-21 |
| US20220402894A1 (en) | 2022-12-22 |
| MX387726B (es) | 2025-03-18 |
| US12145925B2 (en) | 2024-11-19 |
| JP2019522681A (ja) | 2019-08-15 |
| ZA202301066B (en) | 2024-05-30 |
| CN109843874A (zh) | 2019-06-04 |
| CA3029004A1 (en) | 2017-12-28 |
| CN109843874B (zh) | 2022-05-27 |
| EP3475272A1 (en) | 2019-05-01 |
| PT3475272T (pt) | 2023-12-15 |
| ES2964531T3 (es) | 2024-04-08 |
| US20190337928A1 (en) | 2019-11-07 |
| MX2021013641A (es) | 2022-01-06 |
| KR20190033534A (ko) | 2019-03-29 |
| AU2017280334B2 (en) | 2021-07-29 |
| AU2017280334C1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272948A (en) | ENPP1 inhibitors and their use for cancer treatment | |
| EP3490581A4 (en) | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC PROCEDURES FOR TREATMENT OF CANCER | |
| EP3148336A4 (en) | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| IL258854A (en) | Preparations containing cannabidiol and secondary medicinal agents for cancer treatment | |
| IL258741B (en) | Combination of bcl-2 inhibitor and mek inhibitor for cancer treatment | |
| ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
| IL279347A (en) | Gremlin-1 antagonist for cancer prevention and treatment | |
| IL263917A (en) | Pthalazine derivatives as parp1, parp2 and/or tubulin suppressors for use in cancer therapy | |
| EP3600393A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL MALIGNANT TUMORS | |
| IL263697A (en) | Compounds, preparations and methods for the treatment and/or prevention of cancer | |
| IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
| IL247586A0 (en) | Use of Aribolin and mtor inhibitors as a combined treatment for cancer | |
| IL265961A (en) | Use of caspase-3 inhibitors and caspase-3 activators in the preparation of medical preparations for cancer treatment and wound healing | |
| IL253905A0 (en) | Combination of hsp90 inhibitors and pd-1 inhibitors for cancer treatment | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| EP3549608A4 (en) | USE OF A COMBINATION OF A VEGFR INHIBITOR AND PARP INHIBITOR IN THE MANUFACTURING OF A MEDICINAL PRODUCT FOR TREATMENT OF STOMACH CANCER | |
| EP4169918B8 (en) | Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer | |
| IL265824A (en) | Methods and pharmaceutical compositions for the treatment of kidney cancer | |
| SI3630112T1 (sl) | Kombinacija regorafeniba in nivolumaba za zdravljenje raka | |
| EP3654967A4 (en) | USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER | |
| IL255169A0 (en) | Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer | |
| SG11202000724XA (en) | Methods and compositions for the treatment of cancer | |
| IL255168A0 (en) | Treatment combination of an anti-pogatactic factor and an anti-cancer factor and compounds for the treatment of cancer | |
| HK40118235A (zh) | 用於治疗或预防癌症的喹啉衍生物 | |
| HK40029034A (en) | Methods and compositions for the treatment of cancer |